An interventional study of Kava in Tobacco Smoking, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-04.
Sponsored by Masonic Cancer Center, University of Minnesota · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Tobacco Smoking with a site in United States — 24 open to participants now, 30 under way, 2 of them phase 3. Tobacco Smoking · United States.
Among the 186 studies in Tobacco Smoking with a site in United States, this one is the 150th largest by enrollment of the 178 interventional ones that give a count, is one of 5 that started in 2015, is one of 144 with no phase, and was the 29th registered.
265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.
Browse Tobacco Smoking studies →24 of the 186 studies in Tobacco Smoking with a site in United States are open now. Recruiting first, the newest first:
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
Binghamton University · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Tobacco Smoking studies recruiting now, 15 (44%) set no upper age limit and 17 (50%) stop at 75 or younger; 2 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 5 · Phase 4 10
First in 2001; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 120 across 230 interventional studies indexed under Tobacco Smoking.
Median enrollment 111 across the 178 interventional studies, 627 across the 8 observational. Of the 147 that completed or were terminated, 65 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 186 have an industry lead sponsor. The 10 most frequent:
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
Masonic Cancer Center, University of Minnesota has 1 study filed under Tobacco Smoking — fewer than ten, so there is no comparison to draw.
16 of the studies in Tobacco Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03442413University of PennsylvaniaNicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction | 2026-11-22 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT05445804Johns Hopkins UniversityOral Cannabidiol for Tobacco Cessation | 2026-12-01 |
| NCT07598136RAI Services CompanyA Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers | 2026-12-17 |
Add all 16 to your calendar (.ics) → With an account.
Among the 186 studies in Tobacco Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-therapeutic, single-arm pilot clinical trial in adult healthy smokers to assess whether kava can alter NNK metabolism in humans.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate liver and kidney function, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
See intervention description.
Dietary Supplement: Kava
3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 1
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 2
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 4
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 5
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 6
Urinary level (nmol/mL) of total NNAL before and after short-term kava administration
Compare urinary level of total NNAL before and after short-term kava administration
Time frame: Day 7
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 1
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 2
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 4
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 5
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 6
Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration
Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration
Time frame: Day 7
Percentage of subjects experiencing any particular adverse event
Determine the safety of short-term kava administration in healthy smokers
Time frame: Day 4
Percentage of subjects experiencing any particular adverse event
Determine the safety of short-term kava administration in healthy smokers
Time frame: Day 7
O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration
Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration
Time frame: Day 4
O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration
Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration
Time frame: Day 7
Ran from Dec 2015 to primary completion in Mar 2018, 27 months.
Of 112 non-industry interventional studies with no phase under Tobacco Smoking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 27 months is above that.
Counting every sponsor, half of 152 studies reached it within 16 months; a quarter within 4 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piper methysticum root
Masonic Cancer Center, University of Minnesota →